Drosure

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drosure

Property Description
Active ingredient Drospirenone (DRSP), Ethinyl Estradiol (EE)
Form Film-coated tablet
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy
Origin Synthetic (lab-made hormones)

What Type of Medicine is Drosure?

Drosure is a pharmaceutical preparation classified as a combined hormonal contraceptive (CHC), utilized for the prevention of pregnancy. This medication belongs to the comprehensive pharmacological class of Estrogen and Progestin Combinations, signifying that it contains two types of active synthetic female hormones. As an oral contraceptive, it is intended for systemic use by women of reproductive potential and is available only by prescription. The designation as a combined hormonal contraceptive defines the drug’s identity, distinguishing its dual-hormone composition and reliable mechanism from progestin-only pills and non-hormonal methods.

The Active Composition: Drospirenone and Ethinyl Estradiol

The medicine's active components are the synthetic hormones drospirenone (DRSP) and ethinyl estradiol (EE), manufactured chemical entities that establish the drug's fully synthetic origin. The ethinyl estradiol serves as the estrogen component, while drospirenone is the progestin. Drospirenone is notable among progestins due to its unique properties, possessing supplementary anti-mineralocorticoid and antiandrogenic effects. This combination is also found in other established formulations, emphasizing its role in reproductive medicine. The final dosage form is a film-coated tablet intended for oral administration.

General Purpose of the Combined Contraceptive

The singular general therapeutic purpose of this medicine is the effective prevention of pregnancy (contraception). This goal is achieved through the coordinated action of the two hormones, which suppresses the necessary biological steps for conception. The primary mechanism involves inhibiting the monthly release of an egg (ovulation) and creating physical barriers, such as thickening the cervical mucus. These systemic changes establish a highly effective mechanism for achieving controlled contraception.

What side effects are possible with Drosure?

Possible Side Effects and Safety Information

The safety profile of Drosure, a combined hormonal contraceptive containing drospirenone and ethinyl estradiol, is formally structured by government regulatory documents based on frequency and affected body systems.

Frequency-Classified Adverse Reactions

Adverse reactions are classified in regulatory labeling by their frequency observed in clinical studies:

  • Very Common: Headache, breast discomfort, and intermenstrual bleeding (spotting).
  • Common: Nausea, mood changes, depressive mood, migraine, and weight gain. These effects are often documented as being more frequent during the first few cycles of treatment.
  • Rare: Serious reactions such as Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE).

Serious Adverse Reactions and Safety Constraints

The official labels designate Thromboembolic Events (including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke) as rare but serious vascular risks. The risk of VTE is highest during the first year of use.

Due to the drospirenone component, specific population safety constraints are imposed. The medication is formally contraindicated for use in patients with renal impairment, adrenal insufficiency, or severe liver disease to mitigate the risk of hyperkalemia (elevated potassium levels). The risk of serious cardiovascular events is also noted to increase significantly in women who smoke and are over 35 years of age.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

The official regulatory documents define the acute overdose profile for Drosure (Drospirenone/Ethinyl Estradiol) primarily by specific, expected clinical manifestations. The most common documented presentations are gastrointestinal disturbances, including nausea and vomiting. In females and girls, the regulatory information also notes the potential for withdrawal bleeding or vaginal bleeding as a documented clinical sign. Governmental sources generally state that serious adverse effects are not expected following the acute ingestion of multiple doses of this medication.

Management of a suspected overdose is required to be exclusively symptomatic and supportive, as no specific antidote is known to exist for this drug combination.

When to Seek Immediate Medical Help

Immediate medical attention is officially mandated upon the suspicion of overdose. Patients must promptly contact a healthcare professional or emergency medical services regardless of initial symptom severity. This required emergency action ensures that regulatory-defined supportive care is administered. The entire overdose structure is defined by the low acute toxicity classification and the mandatory procedural response needed for any documented symptoms.

Therapeutic Uses of Drosure

This medication is generally used to address three specific therapeutic domains for women of reproductive potential, focusing on control and symptomatic support. These domains include long-term prevention of pregnancy, management of severe symptoms associated with Premenstrual Dysphoric Disorder (PMDD), and symptomatic relief for moderate acne vulgaris.


Primary Use: Contraception and Symptom Support

The medicine's primary domain is long-term pregnancy prevention, which plays a role in managing reproductive control and can assist with maintaining functional stability in personal life planning. Beyond this core use, Drosure is applied in clinical settings marked by heightened, cyclical distress. It helps manage pronounced emotional symptoms (like severe anxiety and irritability) and physical manifestations (such as significant fluid retention and bloating) that interfere with daily functioning. The overall effect is generally supportive relief, as the medication may assist with managing symptoms:

“...provides support that helps ease the overall symptom burden during the perimenstrual phase.”

Furthermore, for women who also desire oral contraception, this medication may be part of symptomatic management for moderate, hormone-sensitive acne vulgaris, contributing to improved comfort and general well-being.


Quick Fact: Support for Cyclical Distress

The medication is relevant in conditions characterized by periods of heightened symptoms, including the severe mood and somatic symptoms associated with PMDD and moderate acne, and may assist with maintaining functional stability.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Who Can and Cannot Use Drosure?

Drosure (Drospirenone/Ethinyl Estradiol) is strictly limited to females of reproductive potential for contraception. For the approved indication of moderate acne, use is restricted to females who are at least 14 years of age, have achieved menarche, and desire birth control. Use is officially not established or not indicated in pre-menarcheal children or elderly women.


Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by women with specific high-risk conditions, primarily related to cardiovascular, hormonal, and organ function risks, as detailed in the regulatory labeling.

Category Population/Condition
Cardiovascular/Thrombotic Smoking and age 35 or older; history of stroke, blood clots, or severe uncontrolled hypertension.
Organ Function Renal impairment, adrenal insufficiency, or hepatic impairment (liver disease or tumors).
Hormonal/Cancer Known or suspected pregnancy; history of breast cancer or other hormone-sensitive cancers; undiagnosed abnormal uterine bleeding.
Concurrent Medication Co-administration with certain Hepatitis C drug combinations.

The medicine is also not recommended during lactation due to the potential for hormone transfer and possible reduction in milk supply.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Drosure (Drospirenone/Ethinyl Estradiol) based on specific pharmacokinetic and pharmacodynamic patterns. Co-administration restrictions are established to manage the efficacy of the contraceptive hormones and the potential for increased potassium levels.

Contraindicated and Restricted Combinations

Combinations with Hepatitis C combination regimens (containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir) are strictly contraindicated due to the documented risk of liver enzyme elevation. Additionally, the co-administration of potassium-sparing diuretics (e.g., spironolactone) is contraindicated in women predisposed to hyperkalemia, such as those with existing renal impairment.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance Categories Official Outcome
Pharmacokinetic (Exposure) CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) May decrease the exposure and effectiveness of the contraceptive hormones.
Pharmacokinetic (Exposure) Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin) Increases the plasma exposure of the drospirenone component.
Pharmacodynamic (Potassium) Potassium-Modulating Drugs (e.g., ACE inhibitors, NSAIDs) May result in an additive hyperkalemic effect due to drospirenone’s anti-mineralocorticoid activity.

For patients receiving co-administration of strong CYP3A4 inhibitors or potassium-modulating drugs, regulatory labels require monitoring of serum potassium concentration during the first cycle. Medicines that are known to be affected by Ethinyl Estradiol, such as Lamotrigine, may also experience reduced plasma concentrations.

Mechanism of Action

Drosure is a selective compound that primarily targets the estrogen receptor alpha (ERalpha) within bone tissue, specifically on osteoblasts. The drug functions as a selective estrogen receptor modulator (SERM). Upon entering the bone microenvironment, Drosure interacts with and activates the ERalpha. This binding event initiates a cell-specific downstream signaling cascade within the osteoblasts.

Activation of this pathway results in a key modulation of the bone remodeling process: the suppression of osteoclast differentiation and activity. Osteoclasts are the cells responsible for bone resorption. By inhibiting these cells, Drosure shifts the balance of bone turnover. The system-level physiological consequence of this targeted action is a net decrease in the rate of bone resorption, thereby altering the bone remodeling equilibrium.

Dosage and Administration Information

How Drosure is Used: Administration Guidelines

Drosure is a combined hormonal contraceptive medication with specific instructions for administration, primarily following a strict, daily, cyclic regimen.


Administration Scope

Instruction Details
Route of administration The product is administered exclusively via the oral route (by mouth).
Dosing schedule The standard regimen is one film-coated tablet daily, following a 28-day cyclic protocol. This consists of a set sequence of active hormone tablets (Drospirenone and Ethinyl Estradiol) and inactive (placebo) tablets.
Timing in relation to meals Drosure can be taken without regard to meals (with or without food). However, the dose should be taken at the same time every day to ensure consistent exposure.
Dose Strengths The medication is available in strengths such as 3 mg Drospirenone / 0.03 mg Ethinyl Estradiol and 3 mg Drospirenone / 0.02 mg Ethinyl Estradiol, depending on the intended use.
Age-group rules The standard regimen applies to adult women of reproductive potential and post-pubertal adolescents (age 14 years and older) for the authorized indications.
Special procedural conditions The tablets must be swallowed whole and taken in the exact order directed on the 28-day blister pack to correctly maintain the prescribed hormone cycle.

Resulting Procedural Structure

The required procedural structure for Drosure use is continuous, long-term cyclic management. The protocol requires starting a new 28-day pack immediately after the last tablet of the previous pack is finished, ensuring no break occurs between courses. Adherence to the sequential order of the active and inactive tablets, combined with fixed daily timing, establishes the necessary systemic context for the medication's intended use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Drosure


Evidence for Use in Preventing Pregnancy

The core evidence researching this formulation for long-term prevention of pregnancy is derived from a combination of randomized controlled trials (RCTs) and very large, long-term observational (epidemiological) studies. Researchers were primarily concerned with measuring contraceptive performance, which is typically quantified using the Pearl Index (a rate of pregnancy per 100 women-years). Studies explored outcomes related to ovulation inhibition and changes in the menstrual cycle. Long-term observational data, which tracked many users over several years, provides context on patterns of cycle control.


Evidence for Use in Managing Severe PMDD Symptoms

Evidence regarding the studies conducted for severe Premenstrual Dysphoric Disorder (PMDD) symptoms comes mainly from short-term, randomized, double-blind, placebo-controlled trials. These studies were designed to rigorously compare the study medication against a placebo over several menstrual cycles. The research primarily monitored the patterns of change in PMDD symptom intensity using standardized scales like the DRSP scale, focusing on outcomes related to functional imbalance.


Evidence Gaps and Areas of Uncertainty

The regulatory research record highlights several areas where certainty remains low or where more data is needed. The follow-up durations were limited for the non-contraceptive indications (three cycles for PMDD and six cycles for acne), meaning long-term research is not fully established for the maintenance of reported symptom changes. A significant placebo effect observed in the PMDD trials is a known factor in symptom-based research. The research results apply only to the specific populations studied, such as women with moderate facial acne who also needed contraception, and there is limited information regarding the medicine’s role in managing milder premenstrual syndrome (PMS) symptoms.

Frequently Asked Questions (FAQ)

Common questions about Drosure (FAQ)

Q: How long does it usually take for Drosure to become fully effective for preventing pregnancy?

Official patient instructions indicate that contraceptive effectiveness is not fully established until after the first seven consecutive days of taking the active tablets. Patients should use a non-hormonal back-up method of birth control during this initial seven-day period of the first cycle to ensure effectiveness.

Q: What are the main medical conditions Drosure is used to treat, besides contraception?

In addition to preventing pregnancy, regulatory documents state that Drosure is officially indicated for the treatment of symptoms of Premenstrual Dysphoric Disorder (PMDD). It is also approved for the treatment of moderate acne in women who have started their menstrual period and who also desire oral contraception.

Q: What is the difference between Drosure and other birth control pills that use different progestins?

The key difference lies in the progestin component, drospirenone. Regulatory information describes drospirenone as a synthetic hormone that possesses anti-mineralocorticoid activity and anti-androgenic effects. This combination of properties gives it different pharmacological effects compared to progestins used in some other oral contraceptives.

Q: How exactly does Drosure work to help with acne or skin issues?

The medicine's components cause an increase in a blood protein called sex hormone binding globulin (SHBG), which can lead to a decrease in the amount of free testosterone in the body. While this action is noted, official labeling notes that the exact relationship between these hormonal changes and the specific decrease in acne severity is not fully established in the documentation.

Q: Is it true that Drosure is sometimes associated with less bloating or water retention compared to other pills?

The drospirenone component in Drosure has anti-mineralocorticoid activity, meaning it can affect the body's salt and water balance. Studies and official information have indicated that, compared to some other formulations, Drosure may be associated with less fluid retention (edema).

Q: Does Drosure increase the risk of gallbladder problems or gallstones?

Regulatory warnings indicate that the use of any combined oral contraceptive, including Drosure, is associated with an increased risk of gallbladder disease. Any concerns about this risk should be discussed with a healthcare provider.

Q: Do headaches or migraines often occur as a side effect when first starting Drosure?

Official product information lists headache as a Very Common side effect. Furthermore, some adverse reactions, including headaches and migraines, have been documented as being more frequent during the first few cycles of treatment as the body adjusts.

Q: What kind of changes to my period, like flow or timing, might be expected when starting Drosure?

Official adverse reaction data shows that users may experience changes such as irregular menstrual periods, heavy non-menstrual vaginal bleeding (spotting), and potentially longer or heavier menstrual periods. Amenorrhea (missing a period) has also been reported.

Q: Why does Drosure have an anti-mineralocorticoid effect, and what does that mean for the body?

The active ingredient drospirenone is chemically similar to the drug spironolactone and has a distinct anti-mineralocorticoid effect. This activity affects the body's handling of fluid and salt. Because of this, official warnings emphasize that there is a potential for hyperkalemia (elevated potassium levels) in high-risk women.

Q: How does the progestin component (drospirenone) in Drosure differ from older progestins?

Official information indicates that drospirenone is unique as a spironolactone analogue. It possesses supplementary effects, namely its anti-mineralocorticoid activity and anti-androgenic effects, which is a distinction from older progestins that may exhibit more androgenic (male hormone-like) effects.

Q: If I notice a decrease in libido while taking Drosure, is that a common side effect?

Regulatory documents list a decreased libido (sex drive) as a Common adverse reaction. This means it is among the side effects that were frequently reported in clinical studies of the medication.

Q: How does Drosure affect a woman's natural hormone levels over time?

The active hormones in Drosure work to prevent pregnancy primarily by inhibiting ovulation—stopping the monthly release of an egg. They also work by altering the cervical mucus and the uterine lining, which disrupts the natural cycle of hormone production and release.

Q: Does Drosure offer any potential benefits for bone mineral density in women?

Official warnings indicate that it is unknown if Drosure may cause a clinically relevant loss of bone mineral density. Therefore, its use has not been established to provide bone health benefits.

Q: Is it safe to switch directly from another hormonal contraceptive to Drosure?

According to official instructions, when switching from another combined oral contraceptive, the patient should start Drosure on the day when the new pack of the previous pill would have typically started. Consult a healthcare professional when making any changes to medication.

Q: Can taking Drosure affect the results of certain lab tests, such as blood work?

Yes, official warnings state that combined oral contraceptives can alter the results of certain laboratory tests. This may include tests that measure hormone-binding proteins like SHBG and blood clotting parameters. Healthcare providers should be informed of Drosure use before any blood work is done.

Q: Is there a specific age limit for starting Drosure for acne treatment?

Official indications limit the use of Drosure for the treatment of acne to females who are at least 14 years of age and have begun their menstrual periods (achieved menarche). It is not for use in children before they have started puberty.

Q: What is the recommendation for using a backup method of contraception when starting Drosure?

Patient instructions specify the use of a non-hormonal contraceptive method as back-up during the first 7 days of the first cycle of Drosure use to ensure contraceptive effectiveness.

Q: Is it normal to have a missed period or amenorrhea while using Drosure as directed?

Official safety information notes that amenorrhea (absence of a period) may occur while using the medication. If a patient misses two consecutive expected periods while adhering to the schedule, regulatory guidance specifies that pregnancy must be ruled out by a healthcare professional.

Q: Does Drosure have any established role in managing symptoms of menopause or hormone replacement?

Official labeling clarifies that Drosure is not indicated for use in elderly women and is not intended for hormone replacement therapy for menopause symptoms.

Q: Can Drosure cause changes in vision or make contact lens use more difficult?

Yes, regulatory data reports contact lens discomfort as a potential side effect. Any significant or sudden changes in vision should be evaluated by a healthcare professional.

Q: How is Drosure metabolized (broken down) by the body?

Official pharmacological data describes how the body breaks down the two active ingredients. The drospirenone component is metabolized mainly through hydroxylation and sulfation. The ethinyl estradiol component is broken down through aromatic hydroxylation to form glucuronide and sulfate conjugates.

Q: Why is it important to take Drosure at the same time every day?

Taking the tablets at the same time every day is essential to help maintain the necessary consistent hormone levels in the body and ensure maximum contraceptive effectiveness. Instructions indicate that fixed daily timing is a strict requirement for administration.

Q: Are there any known interactions between Drosure and herbal supplements like St. John's Wort?

Yes, official drug interaction warnings specifically note that St. John's Wort is a CYP3A4 inducer. Taking this herbal supplement may decrease the exposure and effectiveness of the contraceptive hormones in Drosure.

Q: Is it normal to have light bleeding or 'spotting' during the first few months of taking Drosure?

Official adverse reaction data lists intermenstrual bleeding (spotting) as a Very Common side effect. This irregular bleeding is often transient and is noted to occur more frequently during the first few cycles of use as the body adjusts to the medication.

Q: What should I do if I accidentally miss a non-active (placebo) pill in the Drosure pack?

Official patient instructions advise that if a non-active (reminder) tablet is missed, the patient should simply discard the missed pill(s). They should then continue taking the remaining pills on schedule until the pack is finished.

Q: What is the difference in action between the active and inactive pills in a Drosure pack?

The active pills contain the synthetic hormones ( drospirenone and ethinyl estradiol) and are responsible for preventing pregnancy. The inactive pills are placebo tablets and contain no active medication, serving only to maintain the daily dosing routine.

Q: What is the current medical research saying about the long-term safety profile of Drosure?

Official safety warnings indicate that the risk of Venous Thromboembolism (VTE) is highest during the first year of use, which is a key long-term safety concern. However, official labeling does not provide a general statement on the overall, comprehensive safety profile beyond the known risks.

Q: Why is uncontrolled high blood pressure listed as a potential contraindication for Drosure?

Drosure is contraindicated for use in women with uncontrolled hypertension. This is due to the associated increased risk of serious cardiovascular events, such as stroke or heart attack, when combined with the medication's known vascular risks.

How should Drosure be stored and disposed of?

How to Store and Dispose of Drosure?

Storage Conditions

Official guidance requires Drosure (drospirenone and ethinyl estradiol) tablets to be stored at Controlled Room Temperature, which is 25 C (77 F), with permitted temperature variations ranging from 15 C to 30 C. The tablets must be kept in their original container to maintain product integrity and must be protected from moisture.

Storage Requirement Condition
Temperature 25 C (77 F)
Container Store in original container, protected from moisture
Child Safety Keep out of the reach of children

Disposal Instructions

Unused or expired Drosure must be disposed of according to official regulatory instructions. It is required not to flush the tablets down the toilet or pour them down a drain to prevent environmental contamination. Patients should utilize an official drug take-back program or follow instructions provided by a healthcare professional for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drosure found in:

A-Z Index: